More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$1.19B
EPS
-0.69
P/E ratio
--
Price to sales
1.08
Dividend yield
--
Beta
1.598701
Previous close
$18.48
Today's open
$18.25
Day's range
$17 - $18.64
52 week range
$12.26 - $29.65
show more
CEO
John F. Sheridan
Employees
2500
Headquarters
San Diego, CA
Exchange
NASDAQ Global Market
Shares outstanding
69793846
Issue type
Common Stock
Healthcare
Medical Equipment & Supplies
Tandem: Wait Out The 2027 Transition Before Chasing The Turnaround
I maintain a Hold rating on Tandem Diabetes Care: near-term underperformance offsets significant potential upside after 2027. TNDM's record Q3 revenue rose 13.8%, but international one-offs masked 9% U.S. growth; unchanged FY26 guidance suggests underlying U.S. weakness. PayGo doubles four-year patient revenue to roughly $17,000, but delayed breakeven, attrition risk, and slow pharmacy adoption temper the thesis.
Seeking Alpha • Nov 16, 2026

Tandem Mobi Becomes Only Insulin Pump Offering Both Tubed and Tubeless Wear Options
Global insulin delivery and diabetes technology company Tandem Diabetes Care, Inc. (NASDAQ:TNDM) secured U.S. Food and Drug Administration clearance for Tandem Mobi as the world's first and only tubeless automated insulin delivery system offering up to seven days of wear for users.
Benzinga • Nov 13, 2026

Tandem Mobi Now FDA Cleared as World's First and Only Tubeless AID System with up to Seven Days of Wear
SAN DIEGO--(BUSINESS WIRE)-- #TandemDiabetes--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a global insulin delivery and diabetes technology company, today announced U.S. Food and Drug Administration (FDA) clearance of Tandem Mobi for use as the world's first and only tubeless automated insulin delivery system with up to 7 days of wear.1 A new Tandem Mobi tubeless cartridge and infusion set converts the current Tandem Mobi pump into a tubeless device that can help simplify diabetes management with less frequent si.
Business Wire • Nov 13, 2026

Tandem Diabetes Care Receives Multiple Health Canada Approvals for t:slim X2 Insulin Pump
SAN DIEGO--(BUSINESS WIRE)-- #TandemDiabetes--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced receipt of Health Canada approval of a license amendment for the t:slim X2™ insulin pump with Control-IQ+™ automated insulin delivery (AID) technology. This approval adds compatibility with Abbott's FreeStyle Libre® 3 Plus Sensor and expands the t:slim X2 system's indications for use to people with type 1 diabetes during pregnancy and to adults with.
Business Wire • Nov 12, 2026

What Tandem Diabetes Care (TNDM) Said on Its Q3 Earnings Call
Tandem Diabetes Care NASDAQ: TNDM reported 14% revenue growth in the third quarter of 2026, as higher pump shipments, pharmacy pricing and international sales helped lift gross margin. The company also announced a CEO transition and signaled that a slower-than-expected shift to pharmacy distribution could weigh on revenue growth next year.
MarketBeat • Nov 6, 2026

Tandem Diabetes Care, Inc. (TNDM) Q3 2026 Earnings Call Transcript
Tandem Diabetes Care, Inc. (TNDM) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 6, 2026

Tandem Diabetes Care Announces Third Quarter 2026 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM) (the Company), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended September 30, 2026. Third Quarter 2026 Financial Highlights Sales of $283.7 million worldwide, including $191.0 million in the United States (U.S.) Gross margin of 57%, up 270 basis points compared to third quarter 2025 Pump shipments of approximately 33,000 worldwide, including nearly 23,000 pu.
Business Wire • Nov 5, 2026

Tandem Diabetes Care Names Jeannette Bankes as President and Chief Executive Officer
SAN DIEGO--(BUSINESS WIRE)---- $TNDM #diabetes--Jeannette Bankes named President and CEO of Tandem Diabetes Care in planned transition as John Sheridan Retires After Over a Decade of Service.
Business Wire • Nov 5, 2026

Tandem Diabetes Care (TNDM) Reports Q3 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Tandem Diabetes Care (TNDM) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks Investment Research • Nov 6, 2026

Tandem Diabetes Care, Inc. (TNDM) Reports Q3 Loss, Beats Revenue Estimates
Tandem Diabetes Care, Inc. (TNDM) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to a loss of $0.31 per share a year ago.
Zacks Investment Research • Nov 5, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Tandem Diabetes Care Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.